SLC13A5 and osteoporosis: In contrast, for genetically predicted SLC13A5 inhibition a significant lower risk of osteoporosis emerged both for diagnosed (−0.0016; 95% CI −0.0021 to −0.0011; p = 2.3 × 10−3) and for self-reported cases (−0.0034; 95% CI −0.0047 to −0.0021; p = 9.7 × 10−3).